These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 11862306)

  • 1. A New Look At United States Drug Development and Approval Times.
    DiMasi JA
    Am J Ther; 1996 Sep; 3(9):647-657. PubMed ID: 11862306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The new drug approvals of 1987, 1988, and 1989: trends in drug development.
    Kaitin KI; DiCerbo PA; Lasagna L
    J Clin Pharmacol; 1991 Feb; 31(2):116-22. PubMed ID: 2010558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The new drug approvals of 1990, 1991, and 1992: trends in drug development.
    Kaitin KI; Manocchia M; Seibring M; Lasagna L
    J Clin Pharmacol; 1994 Feb; 34(2):120-7. PubMed ID: 8163711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA advisory committees and the new drug approval process.
    Kaitin KI; Melville A; Morris B
    J Clin Pharmacol; 1989 Oct; 29(10):886-90. PubMed ID: 2592579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in drug development: the 1985-86 new drug approvals.
    Kaitin KI; Richard BW; Lasagna L
    J Clin Pharmacol; 1987 Aug; 27(8):542-8. PubMed ID: 3655005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The new drug approvals of 1993, 1994, and 1995: trends in drug development.
    Kaitin KI; Manocchia M
    Am J Ther; 1997 Jan; 4(1):46-54. PubMed ID: 10423591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rate of development of new drugs in the United States, 1963 through 1975.
    Wardell WM; Hassar M; Anavekar SN; Lasagna L
    Clin Pharmacol Ther; 1978 Aug; 24(2):133-45. PubMed ID: 679593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New drug development by United States pharmaceutical firms with analyses of trends in the acquisition and origin of drug candidates, 1963-1979.
    Wardell WM; May MS; Trimble AG
    Clin Pharmacol Ther; 1982 Oct; 32(4):407-17. PubMed ID: 7116754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prescription Drug User Fee Act of 1992 and the new drug development process.
    Kaitin KI
    Am J Ther; 1997; 4(5-6):167-72. PubMed ID: 10423607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory review intervals for ophthalmic new drug applications at the US Food and Drug Administration.
    Novack GD
    Am J Ophthalmol; 1998 Jul; 126(1):122-6. PubMed ID: 9683158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Drug Lags in Development Initiation, New Drug Application and Approval Between Japan and the USA and the Impact of Local Versus Multi-regional Clinical Trials.
    Ushijima S; Matsumaru N; Tsukamoto K
    Pharmaceut Med; 2021 Jul; 35(4):253-260. PubMed ID: 34291425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drug approval times and clinical evidence in Japan.
    Ono S; Yoshioka C; Asaka O; Tamura K; Shibata T; Saito K
    Contemp Clin Trials; 2005 Dec; 26(6):660-72. PubMed ID: 16122988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New drug development during and after a period of regulatory change: clinical research activity of major United States pharmaceutical firms, 1958 to 1979.
    May MS; Wardell WM; Lasagna L
    Clin Pharmacol Ther; 1983 Jun; 33(6):691-700. PubMed ID: 6851401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gadofosveset: MS 325, MS 32520, Vasovist, ZK 236018.
    Drugs R D; 2004; 5(6):339-42. PubMed ID: 15563237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of regulatory approval times for new chemical entities in Australia, Canada, Sweden, the United Kingdom, and the United States.
    Pieterson EA
    J Clin Pharmacol; 1992 Oct; 32(10):889-96. PubMed ID: 1447395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abarelix: abarelix-depot-F, abarelix-depot-M, abarelix-L, PPI 149, R 3827.
    Drugs R D; 2003; 4(3):161-6. PubMed ID: 12757402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of Drugs Approved via the 505(b)(2) Pathway: Uncovering Drug Development Trends and Regulatory Requirements.
    Freije I; Lamouche S; Tanguay M
    Ther Innov Regul Sci; 2020 Jan; 54(1):128-138. PubMed ID: 32008242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in the Review Period of Drug Application and a Drug Lag from the FDA and the EMA: An Industry Survey in South Korea Between 2011 and 2020.
    Choi H; Lee H; Park B; Kim C; Lee J
    Ther Innov Regul Sci; 2023 May; 57(3):552-560. PubMed ID: 36539577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.